Charles River Laboratories International, Inc. (NYSE:CRL) Stock Holdings Increased by Centiva Capital LP

Centiva Capital LP boosted its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 58.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 11,511 shares of the medical research company's stock after acquiring an additional 4,246 shares during the quarter. Centiva Capital LP's holdings in Charles River Laboratories International were worth $2,125,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Veracity Capital LLC purchased a new position in shares of Charles River Laboratories International during the 4th quarter worth $589,000. Allspring Global Investments Holdings LLC lifted its holdings in Charles River Laboratories International by 2.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock valued at $330,231,000 after acquiring an additional 47,221 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Charles River Laboratories International by 46.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company's stock valued at $987,000 after acquiring an additional 1,679 shares during the last quarter. Boston Trust Walden Corp lifted its stake in Charles River Laboratories International by 4.3% during the fourth quarter. Boston Trust Walden Corp now owns 204,483 shares of the medical research company's stock worth $37,748,000 after purchasing an additional 8,338 shares in the last quarter. Finally, E. Ohman J or Asset Management AB grew its position in Charles River Laboratories International by 225.0% in the 4th quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company's stock valued at $480,000 after acquiring an additional 1,800 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock traded up $4.61 during trading hours on Monday, hitting $143.40. The stock had a trading volume of 649,439 shares, compared to its average volume of 965,563. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The stock's fifty day moving average is $138.40 and its two-hundred day moving average is $166.20. The stock has a market capitalization of $7.04 billion, a price-to-earnings ratio of 954.55, a PEG ratio of 4.54 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same period in the previous year, the firm posted $2.27 EPS. Charles River Laboratories International's revenue was down 2.7% on a year-over-year basis. As a group, analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other news, CEO James C. Foster acquired 6,075 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was acquired at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now directly owns 183,639 shares in the company, valued at approximately $30,302,271.39. This represents a 3.42% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. The trade was a 18.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

CRL has been the subject of several research reports. Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price for the company in a research report on Monday, March 3rd. Robert W. Baird increased their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research note on Thursday. Mizuho dropped their target price on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. Morgan Stanley dropped their target price on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 5th. Finally, JPMorgan Chase & Co. lowered their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International currently has an average rating of "Hold" and a consensus target price of $176.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).